Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDA: Oral Vancomycin in Paediatric IBD
NCT07646223Phase 2Not yet recruiting
- Sponsor
- Tampere University Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2032
- Countries
- 1
01
Overview
A Phase 2 trial of vancomycin in ulcerative colitis (UC), Primary Sclerosing Cholangitis (PSC), sponsored by Tampere University Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
vancomycin
03
Conditions
ulcerative colitis (UC)Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT07646223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646223.